Toxicities Associated with Head and Neck Cancer Treatment and Oncology-Related Clinical Trials

Abstract:
Approximately 600,000 new cases of head and neck cancer (HNC) would be diagnosed worldwide this year. Of those, a bit less than 10% would occur in the United States. Most of these neoplasms would be histologically diagnosed as a squamous cell carcinomas for which the preferred treatment typically consists of a multimodality approach that includes local resection followed by a course of concomitant chemoradiation in which radiosensitizing chemotherapy (most commonly cisplatin) is coupled with cumulative radiation doses of 60-70 Gy given in 1.8-2.2 Gy daily fractions.

Read Full Publication